Full-Time

Customer Support Specialist 3

Posted on 8/7/2025

Deadline 10/31/25
Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Phoenix, AZ, USA

In Person

Category
Customer Experience & Support (1)
Requirements
  • Requires broad training in fields such Computer Science, IT Management, or MSIS generally obtained through completion of a four year bachelor’s degree program or equivalent combination of experience and education; normally requires at least five (5) years directly related and progressively responsible experience with overall information technologies.
  • 5 or more years of advanced experience working with computer technology in a business environment.
  • Desktop, laptop, tablet, thin client and mobile device hardware fundamentals.
  • Strong analytical, conceptual and problem solving skills to evaluate business problems and apply knowledge to identify appropriate solutions.
  • Ability to recognize & identify network and server access problems for end users.
  • Ability to troubleshoot and resolve issues with WAN, LAN, VPN, etc. for local and remote access events.
  • Troubleshoot and resolve issues with voice communications (i.e., PBX telephone) and voice mail systems, when possible from the Help Desk.
  • Comprehensive computer skills; Microsoft Office Software, Windows platforms, Apple iOS, Windows 7, 8, 8.1, Macintosh OS X, VM Ware, VM Fusion, Active Directory, GPO and other company and application-specific software.
  • Ability to communicate effectively both orally and in writing.
  • Ability to communicate with associates, including executive-level associates and their administrative assistants.
  • Strong teamwork and interpersonal skills.
Responsibilities
  • Provide support for desktop, laptop, tablet, thin client, mobile devices, conference room technologies, and any associated peripherals and components such a thin clients, printers, fax machines, and other end-user technologies.
  • Perform advanced nth level assessment and resolution on problems, working with manufacturers/vendors as needed.
  • Coordinate problem resolution among a variety of functional areas and provides subject matter expertise support for diagnosing and resolving problem.
  • Provide guidance to other team members.
  • Designs and deploys EndPoint Support Processes.
  • Partner with network and systems administration teams to ensure efficient operation of the desktop computing environment.
  • May participate in R&D efforts.
  • Plans and schedules the installation and deployment projects.
  • Leads the planning, building, upgrading, and maintenance of endpoint support projects.
  • Diagnose, identify, isolate and analyze problems based on information presented by end users.
  • Resolve technical problems and answer questions by phone as necessary in support of end-user infrastructure technologies.
  • Provide highly complex maintenance and support for endpoint devices.
  • Lead multiple projects/work initiatives/tasks concurrently.
  • Alert management to recurring problems and patterns of problems that may be widespread or affecting our associates.
  • Route calls to Infrastructure Tower Leads, external vendors, and the Management Team as required.
  • Provides recommendations for end user technology based on historical problem solving and experience.
  • Participates in the setup and support of Proof of Concept (POC) initiatives and emerging technologies that are introduced into the environment.
  • Interacts regularly with other technology teams as well as external vendors for the purpose of maintaining product and system knowledge.
  • Performs related duties as assigned.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • Specialty pharmaceuticals remain the main growth engine for higher-margin services.
  • Management targets $300 million in savings while sustaining about $3 billion free cash flow.
  • Share repurchases and accretive acquisitions can support earnings per share.

What critics are saying

  • Biosimilar conversions are cutting revenue growth at major mail-order pharmacy customers.
  • Manufacturer list-price cuts created a $2 billion quarterly revenue headwind.
  • Customer losses and slower GLP-1 growth weaken Cencora's specialty mix.

What makes Cencora unique

  • Cencora combines drug distribution, specialty pharmacy, and patient-support services.
  • It operates globally, serving manufacturers, providers, pharmacies, and veterinary customers.
  • The company is expanding specialty care through OneOncology and EyeSouth retina assets.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Cencora who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE